Innovator’s Pitch Challenge
EicOsis is a clinical stage company targeting the soluble epoxide hydrolase (sEH) to increase regulatory lipids that naturally resolve inflammation and treat pain and neuroinflammation. EicOsis is developing EC5026, an orally bioavailable, small molecule, nanomolar inhibitor of sEH that has shown efficacy in treating inflammatory and neuropathic pain in preclinical studies. Our lead indication for treating pain has been validated clinically in natural diseases in horses (laminitis) and dogs (osteoarthritis), thereby derisking the translation of preclinical efficacy data to human clinical trials. Our preclinical data indicate that our compounds have an efficacy and safety profile that meets or exceeds that of approved pain drugs, but without adverse effects on the central nervous system (e.g. sedation, confusion, respiratory depression), cardiovascular, or GI system. Our preclinical data also indicates there is unlikely to be addiction liability. EicOsis is seeking funding for phase 1b and clinical proof of concept studies.